Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
Hybrids composed of various materials are highly versatile for drug delivery in tumor therapy including hepatocellular carcinoma. Herein, a sorafenib (SF)-loaded biomacromolecule hyaluronic acid (HA)/lipid hybrid nanoparticles (HA/SF-cLNS) were developed for targeting drug delivery.



In vitro assays determined HA/SF-cLNS release behavior, enzymatic degradation, uptake and cytotoxicity. H22-bearing liver cancer xenograft murine models were used to evaluate the biodistribution and therapeutic efficacy in vivo.



HA/SF-cLNS could be disassembled and drug was released in response to hyaluronidase. In vivo imaging results demonstrated HA/cLNS could enhance drug accumulation at tumor site. Meanwhile, HA/SF-cLNS exhibited improved antitumor efficacy in vitro and in vivo.



HA/SF-cLNS demonstrated the potential to enhance antitumor efficacy of SF.
School of Pharmaceutical Sciences, Shandong University, Jinan 250012, People's Republic of China.
Jing
J
Zhang
School of Pharmaceutical Sciences, Shandong University, Jinan 250012, People's Republic of China.
Tianqi
T
Wang
School of Pharmaceutical Sciences, Shandong University, Jinan 250012, People's Republic of China.
Shengjun
S
Mu
School of Pharmaceutical Sciences, Shandong University, Jinan 250012, People's Republic of China.
Livesey D
LD
Olerile
School of Pharmaceutical Sciences, Shandong University, Jinan 250012, People's Republic of China.
Xiaoyue
X
Yu
School of Pharmaceutical Sciences, Shandong University, Jinan 250012, People's Republic of China.
Na
N
Zhang
D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D002470:Cell Survival / Q000187:drug effects; D016503:Drug Delivery Systems; D056945:Hep G2 Cells; D006801:Humans; D008055:Lipids / Q000008:administration & dosage / Q000737:chemistry; D008113:Liver Neoplasms / Q000188:drug therapy*; D051379:Mice; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry; D010671:Phenylurea Compounds / Q000008:administration & dosage* / Q000737:chemistry; D000077157:Sorafenib; D023041:Xenograft Model Antitumor Assays
D008055:Lipids; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib
HCC; biomacromolecule/lipid hybrid nanoparticles; enzyme-responsive; hyaluronic acid; sorafenib